1 min read
Selexis SA to Present and Partner at the BIO-Europe 2011 Partnering Conference
Dr. Igor Fisch to Present in the Discovery Platform Track
Geneva, Switzerland (PRNEWSWIRE) October 20, 2011 – Selexis...
Dr. Igor Fisch to Present in the Discovery Platform Track
Geneva, Switzerland (PRNEWSWIRE) October 20, 2011 – Selexis...
Geneva, Switzerland (PRNEWSWIRE) October 21, 2011 – Selexis SA announced today data from the Company’s SUREtechnology...
Experts will Drive the Company’s Technology Development for Drug Discovery
Geneva, Switzerland (PRNEWSWIRE) September...
Dr. Pierre-Allain Girod to Present on Data on Engineering CHO Cell Lines for Enhanced Production of Monoclonal...
CSL Limited Signs Commercial License Agreement with Selexis SCSL Limited will use Selexis Technologies for Development...
Geneva, Switzerland (PRWEB) July 13, 2011 – Selexis SA, a global life science company with technologies for drug...
Dr. Igor Fisch to Present Data on Company’s New Designer CHO Cell Lines Developed to Overcome Protein Expression...
Celebrating Launch of New Service in Support of Biologic Lead Identification
Geneva, Switzerland (PRWEB) June 24, 2011...
Selexis to Meet with Companies Interested in Mammalian Cell Line Development, Lead Identification for Therapeutic Drug...
Geneva, Switzerland (PRWEB) April 19, 2011 – Selexis SA, a Swiss-based biotechnology company with technologies for the...
Major Milestone Will Speed Regulatory Filings for Recombinant Protein Therapeutics and Monoclonal Antibodies Developed...
Geneva, Switzerland (PRWEB) March 11, 2011 – Selexis SA, a Swiss-based biotechnology company with technologies for the...
Geneva, Switzerland (PRWEB) March 9, 2011 – Selexis SA, a Swiss-based biotechnology company with technologies for the...
New Service Will Speed Library Screening Campaigns
Geneva, Switzerland (PRWEB) March 08, 2011 – Selexis SA, a...
Major Expansion Includes Protein Purification Unit
Geneva, Switzerland (PRWEB) February 9, 2011, Selexis SA, a...
Geneva, Switzerland, January 5, 2011 Selexis SA, a Swiss-based biotechnology company offering technologies and services...
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.